American Regent, Inc.

PACLITAXEL PROTEIN-BOUND (AMERICAN REGENT)

Manufacturer:

American Regent, Inc.

Paclitaxel Protein-Bound (American Regent) HCPCS:

J9259

HCPCS Code Descriptor:

Injection, paclitaxel protein-bound particles (american regent) not therapeutically equivalent to j9264, 1 mg

Category:

J Code

Paclitaxel Protein-Bound (American Regent) NDCs:

00517-4300-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Paclitaxel Protein-Bound (American Regent):

PACLITAXEL PROTEIN-BOUND (AMERICAN REGENT) is a Oncology drug manufactured by American Regent, Inc. and administered via the Intravenous route of administration. The J Code: J9259 is aligned to the drug PACLITAXEL PROTEIN-BOUND (AMERICAN REGENT) .

ACCESS PRICING AND MORE BY REGISTERING

J9259 Added Date:

July 1, 2023

J9259 Effective Date:

July 1, 2023

J9259 Termination Date:

HCPCS Active

Paclitaxel Protein-Bound (American Regent) billing and coding information can be found through American Regent, Inc. at the link below:
Our team did not identify a source for Paclitaxel Protein-Bound (American Regent) patient assistance information. Please reach out to our team if you feel that this is a mistake.
PACLITAXEL PROTEIN-BOUND (AMERICAN REGENT) prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for PACLITAXEL PROTEIN-BOUND (AMERICAN REGENT). Please check back in a few weeks.